Back to News
Market Impact: 0.2
Celaid Therapeutics Completes Second Close of Series B Financing Round
Source: PR Newswire
Healthcare & BiotechPrivate Markets & Venture
Celaid Therapeutics announced that Shionogi & Co. and Teikoku Ventures joined a funding round to accelerate U.S. clinical-trial preparations for CLD-001. The available article text provides no funding amount, trial timeline, or additional details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Nvidia-backed Reflection AI unveils its first open model, Beam. Could it be America’s best chance to compete with China?
- Up 57% since June: this AI-picked pharma stock keeps climbing
- Why is NeoGenomics stock sliding today?
- Nvidia backs startup Reactor as buzz grows for world models
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data